Orchestra BioMed Holdings (OBIO) Cash from Investing Activities (2022 - 2026)

Orchestra BioMed Holdings (OBIO) has 5 years of Cash from Investing Activities data on file, last reported at $10.3 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 20.62% year-over-year to $10.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$29.6 million (down 246.45% YoY) and the FY2025 annual result came in at -$26.9 million, down 305.83% from the prior year.
• Cash from Investing Activities grew to $10.3 million in Q1 2026 per OBIO's latest filing, from -$17.7 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $33.2 million in Q4 2023 and bottomed at -$63.4 million in Q4 2022.
• The 5-year median for Cash from Investing Activities is $557000.0 (2024), against an average of -$3.4 million.
• Peak annual rise in Cash from Investing Activities reached 5879.91% in 2023, while the deepest fall reached 92514.89% in 2023.
• Tracing OBIO's Cash from Investing Activities over 5 years: stood at -$63.4 million in 2022, then surged by 152.31% to $33.2 million in 2023, then plunged by 111.32% to -$3.8 million in 2024, then sank by 371.94% to -$17.7 million in 2025, then surged by 158.25% to $10.3 million in 2026.
• Per Business Quant, the three latest OBIO Cash from Investing Activities figures stand at $10.3 million (Q1 2026), -$17.7 million (Q4 2025), and -$38.6 million (Q3 2025).

Peer Comparison